Salahuddin M, Salamo O, Karanth S, Faiz SA, Estrada-Y-Martin RM, Cherian SV. Safety and incidence of complications associated with bronchoscopy in an obese population. Clin Respir J. 2021 Jun;15(6):670-5. doi: 10.1111/crj.13342
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Montserrat-Capdevila J, Godoy P, Marsal JR, Cruz I, Solanes M. Effectiveness of influenza vaccination in preventing hospital admission due to exacerbations of chronic obstructive pulmonary disease. Enferm Infecc Microbiol Clin. 2014 Feb;32(2):70-5. doi: 10.1016/j.eimc.2013.02.009
Smets E, Brogan AJ, Hill A, Adriaenssen I, Sawyer AW, Domingo-Pedrol P, Gostkorzewicz J, Ledesma F. Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain. Enferm Infecc Microbiol Clin. 2013 Aug;31(7):430-6.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Serna MC, Real J, Ribes E, Marsal JR, Godoy P, Galvin L. Factors determining antibiotic prescription in primary care. Enferm Infecc Microbiol Clin. 2011 Mar;29(3):193-200. doi: 10.1016/j.eimc.2010.09.012
Brodtkorb T, Zetterström O, Tinghög G. Cost-effectiveness of clean air administered to the breathing zone in allergic asthma. Clin Respir J. 2010;4(2):104-10.
Nguyen USDT, Rothman KJ, Demissie S, Jackson DJ, Lang JM, Ecker JL. Transfers among women intending a birth center delivery in the San Diego birth center study. J Midwifery Womens Health. 2009 Mar 1;54(2):104-10.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.